{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:01:43Z","timestamp":1785492103557,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00152-3","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:56:39Z","timestamp":1785491799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["2026 Korean expert recommendations for the use of thrombopoietin receptor agonists in severe aplastic anemia"],"prefix":"10.1007","volume":"61","author":[{"given":"Silvia","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Ho","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ik-Chan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo-Yeon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeung-Chul","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"152_CR1","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/S0301-472X(01)00736-6","volume":"29","author":"H Kook","year":"2001","unstructured":"Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol. 2001;29:1270\u20137.","journal-title":"Exp Hematol"},{"key":"152_CR2","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra1413485","volume":"379","author":"NS Young","year":"2018","unstructured":"Young NS. Aplastic anemia. N Engl J Med. 2018;379:1643\u201356.","journal-title":"N Engl J Med"},{"key":"152_CR3","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/jcp.1041650312","volume":"165","author":"C Selleri","year":"1995","unstructured":"Selleri C, Sato T, Anderson S, Young NS, Maciejewski JP. Interferon-\u03b3 and tumor necrosis factor-\u03b1 suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol. 1995;165:538\u201346.","journal-title":"J Cell Physiol"},{"key":"152_CR4","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jtct.2024.09.017","volume":"30","author":"R Iftikhar","year":"2024","unstructured":"Iftikhar R, DeFilipp Z, DeZern AE, Pulsipher MA, Bejanyan N, Burroughs LM. Allogeneic hematopoietic cell transplantation for the treatment of severe aplastic anemia: evidence-based guidelines from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2024;30:1155\u201370.","journal-title":"Transplant Cell Ther"},{"key":"152_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/j.seminhematol.2022.01.002","volume":"59","author":"BA Patel","year":"2022","unstructured":"Patel BA, Townsley DM, Scheinberg P. Immunosuppressive therapy in severe aplastic anemia. Semin Hematol. 2022;59:21\u20139.","journal-title":"Semin Hematol"},{"key":"152_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1378432","volume":"15","author":"A Piekarska","year":"2024","unstructured":"Piekarska A, Pawelec K, Szmigielska-Kap\u0142on A, Ussowicz M. The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults. Front Immunol. 2024;15:1378432.","journal-title":"Front Immunol"},{"key":"152_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1200\/JCO.22.00710","volume":"41","author":"C Gurnari","year":"2023","unstructured":"Gurnari C, Pagliuca S, Prata PH, Galimard JE, Catto LFB, Larcher L. Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria. J Clin Oncol. 2023;41:132\u201342.","journal-title":"J Clin Oncol"},{"key":"152_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/ajh.23692","volume":"89","author":"P Scheinberg","year":"2014","unstructured":"Scheinberg P, Rios O, Scheinberg P, Weinstein B, Wu CO, Young NS. Prolonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia. Am J Hematol. 2014;89:571\u20134.","journal-title":"Am J Hematol"},{"key":"152_CR9","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s00277-020-04271-4","volume":"99","author":"B Drexler","year":"2020","unstructured":"Drexler B, Zurbriggen F, Diesch T, Viollier R, Halter JP, Heim D. Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation. Ann Hematol. 2020;99:2529\u201338.","journal-title":"Ann Hematol"},{"key":"152_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/1110-1067.186414","volume":"41","author":"AM El Afifi","year":"2016","unstructured":"El Afifi AM, El Zemaity M, Mostafa NN, Moussa M, Kamal GM, Magdy R. Effect of comorbidities on hematopoietic stem cell transplantation outcome in adult patients with different hematologic diseases: a single-center experience in Egypt. Egypt J Haematol. 2016;41:100\u20135.","journal-title":"Egypt J Haematol"},{"key":"152_CR11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ajh.27611","volume":"100","author":"B Fattizzo","year":"2025","unstructured":"Fattizzo B, Gurnari C, Giammarco S, Ricchiuti A, Awada H, Bortolotti M. Elderly patients with aplastic anemia: treatment patterns and outcomes in the real world. Am J Hematol. 2025;100:584\u201391.","journal-title":"Am J Hematol"},{"key":"152_CR12","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1182\/blood-2017-09-807859","volume":"131","author":"S Giammarco","year":"2018","unstructured":"Giammarco S, Peffault de Latour R, Sica S, Dufour C, Socie G, Passweg J. Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved? Blood. 2018;131:1989\u201392.","journal-title":"Blood"},{"key":"152_CR13","doi-asserted-by":"publisher","first-page":"204062072199812","DOI":"10.1177\/2040620721998126","volume":"12","author":"B Drexler","year":"2021","unstructured":"Drexler B, Passweg JR. Current evidence and the emerging role of eltrombopag in severe aplastic anemia. Ther Adv Hematol. 2021;12:2040620721998126.","journal-title":"Ther Adv Hematol"},{"key":"152_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1053\/j.seminhematol.2019.09.001","volume":"56","author":"JB Bussel","year":"2019","unstructured":"Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Rivero C, Heller PG. Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. Semin Hematol. 2019;56:262\u201378.","journal-title":"Semin Hematol"},{"key":"152_CR15","doi-asserted-by":"publisher","first-page":"5719","DOI":"10.1182\/bloodadvances.2024013529","volume":"8","author":"P Scheinberg","year":"2024","unstructured":"Scheinberg P, Kulasekararaj AG. Consensus recommendations for severe aplastic anemia. Blood Adv. 2024;8:5719\u201320.","journal-title":"Blood Adv"},{"key":"152_CR16","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.19236","volume":"204","author":"A Kulasekararaj","year":"2024","unstructured":"Kulasekararaj A, Cavenagh J, Dokal I, Foukaneli T, Gandhi S, Garg M. Guidelines for the diagnosis and management of adult aplastic anaemia: a British Society for Haematology Guideline. Br J Haematol. 2024;204:784\u2013804.","journal-title":"Br J Haematol"},{"key":"152_CR17","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1182\/bloodadvances.2023011642","volume":"8","author":"DV Babushok","year":"2024","unstructured":"Babushok DV, DeZern AE, de Castro CM, Rogers ZR, Beenhouwer D, Broder MS. Modified Delphi panel consensus recommendations for management of severe aplastic anemia. Blood Adv. 2024;8:3946\u201360.","journal-title":"Blood Adv"},{"key":"152_CR18","first-page":"572","volume":"66","author":"K Hosokawa","year":"2025","unstructured":"Hosokawa K. A new era in the treatment of aplastic anemia. Rinsho Ketsueki. 2025;66:572\u20139.","journal-title":"Rinsho Ketsueki"},{"key":"152_CR19","first-page":"1969","volume":"59","author":"H Yamazaki","year":"2018","unstructured":"Yamazaki H. Treatment strategy for acquired aplastic anemia. Rinsho Ketsueki. 2018;59:1969\u201378.","journal-title":"Rinsho Ketsueki"},{"key":"152_CR20","doi-asserted-by":"crossref","unstructured":"Passweg JR, Baldomero H, Atlija M, Kleovoulou I, Witaszek A, Alexander T. The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT. Bone Marrow Transplant 2025;60:519\u201328.","DOI":"10.1038\/s41409-025-02524-2"},{"key":"152_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1200931","volume":"367","author":"MJ Olnes","year":"2012","unstructured":"Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11\u20139.","journal-title":"N Engl J Med"},{"key":"152_CR22","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","volume":"123","author":"R Desmond","year":"2014","unstructured":"Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123:1818\u201325.","journal-title":"Blood"},{"key":"152_CR23","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","volume":"376","author":"DM Townsley","year":"2017","unstructured":"Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376:1540\u201350.","journal-title":"N Engl J Med"},{"key":"152_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2109965","volume":"386","author":"R Peffault de Latour","year":"2022","unstructured":"Peffault de Latour R, Kulasekararaj A, Iacobelli S, Terwel SR, Cook R, Griffin M. Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med. 2022;386:11\u201323.","journal-title":"N Engl J Med"},{"key":"152_CR25","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.1016\/S2352-3026(19)30153-X","volume":"6","author":"JW Lee","year":"2019","unstructured":"Lee JW, Lee SE, Jung CW, Park S, Keta H, Park SK. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol. 2019;6:e562\u201372.","journal-title":"Lancet Haematol"},{"key":"152_CR26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bjh.17190","volume":"192","author":"JH Jang","year":"2021","unstructured":"Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N. Efficacy and safety of romiplostim in refractory aplastic anaemia: a phase II\/III, multicentre, open-label study. Br J Haematol. 2021;192:190\u20139.","journal-title":"Br J Haematol"},{"key":"152_CR27","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1182\/bloodadvances.2024014855","volume":"9","author":"JW Lee","year":"2025","unstructured":"Lee JW, Jang JH, Yamazaki H, Sawa M, Kizaki M, Tomiyama Y. Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia. Blood Adv. 2025;9:5732\u20135.","journal-title":"Blood Adv"},{"key":"152_CR28","unstructured":"Yeh SP. Aplastic anemia in Taiwan. 2nd Asian Bone Marrow Failure Syndromes Symposium. Seoul, Korea, 2026."},{"key":"152_CR29","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1056\/NEJMoa1103975","volume":"365","author":"P Scheinberg","year":"2011","unstructured":"Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365:430\u20138.","journal-title":"N Engl J Med"},{"key":"152_CR30","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s12185-017-2179-3","volume":"105","author":"J Hayakawa","year":"2017","unstructured":"Hayakawa J, Kanda J, Akahoshi S, Harada K, Akasaka H, Komatsu T. Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia. Int J Hematol. 2017;105:578\u201386.","journal-title":"Int J Hematol"},{"key":"152_CR31","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00277-013-1674-8","volume":"92","author":"SH Shin","year":"2013","unstructured":"Shin SH, Yoon JH, Yahng SA, Lee SE, Cho BS, Eom KS. The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol. 2013;92:817\u201324.","journal-title":"Ann Hematol"},{"key":"152_CR32","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/blood.V118.21.2399.2399","volume":"118","author":"X Feng","year":"2011","unstructured":"Feng X, Scheinberg P, Biancotto A, Rios O, Donaldson S, Wu CO. Different in vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia. Blood. 2011;118:508.","journal-title":"Blood"},{"key":"152_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-015-0173-x","volume":"8","author":"PT Vo","year":"2015","unstructured":"Vo PT, Pantin J, Ramos C, Cook L, Cho E, Kurlander R. Conditioning with rabbit versus horse ATG dramatically alters clinical outcomes in identical twins with severe aplastic anemia transplanted with the same allogeneic donor. J Hematol Oncol. 2015;8:78.","journal-title":"J Hematol Oncol"},{"key":"152_CR34","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1177\/0091270010375427","volume":"51","author":"E Gibiansky","year":"2011","unstructured":"Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2011;51:842\u201356.","journal-title":"J Clin Pharmacol"},{"key":"152_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3999\/jscpt.42.11","volume":"42","author":"Y Shida","year":"2011","unstructured":"Shida Y, Takahashi N, Nohda S, Hirama T. Pharmacokinetics and pharmacodynamics of eltrombopag in healthy Japanese males. Rinsho Yakuri. 2011;42:11\u201320.","journal-title":"Rinsho Yakuri"},{"key":"152_CR36","unstructured":"Min KI. Real-world experience with eltrombopag and romiplostim as second-line therapy for relapsed or refractory aplastic anemia. ICKSH 2025. Seoul, Korea, 2025."},{"key":"152_CR37","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3904\/kjim.2014.29.6.713","volume":"29","author":"SH Shin","year":"2014","unstructured":"Shin SH, Lee SE, Lee JW. Recent advances in treatment of aplastic anemia. Korean J Intern Med. 2014;29:713\u201326.","journal-title":"Korean J Intern Med"},{"key":"152_CR38","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bjh.19648","volume":"205","author":"A Prabahran","year":"2024","unstructured":"Prabahran A, Durrani J, Coelho-Da Silva J, Shalhoub R, Lotter J, Rios O. Safety and efficacy of immunosuppressive therapy for elderly patients with severe aplastic anaemia. Br J Haematol. 2024;205:1170\u20139.","journal-title":"Br J Haematol"},{"key":"152_CR39","first-page":"29","volume":"45","author":"D Bunn","year":"1996","unstructured":"Bunn D, Lea CK, Bevan DJ, Neuberger J, Adu D. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol. 1996;45:29\u201332.","journal-title":"Clin Nephrol"},{"key":"152_CR40","volume-title":"ATGAM (lymphocyte immune globulin, anti-thymocyte globulin [equine]) [package insert]","author":"P Inc","year":"2023","unstructured":"Inc P. ATGAM (lymphocyte immune globulin, anti-thymocyte globulin [equine]) [package insert]. New York (NY): Pfizer Inc.; 2023."},{"key":"152_CR41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.33590\/emj\/10312801","volume":"3","author":"H Rho","year":"2018","unstructured":"Rho H, Wells RA. A game of clones: the complex interplay of aplastic anaemia, myelodysplastic syndrome, and paroxysmal nocturnal haemoglobinuria. EMJ. 2018;3:108\u201315.","journal-title":"EMJ"},{"key":"152_CR42","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jama.2010.1376","volume":"304","author":"P Scheinberg","year":"2010","unstructured":"Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA. 2010;304:1358\u201364.","journal-title":"JAMA"},{"key":"152_CR43","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/bjh.20206","volume":"207","author":"JW Lee","year":"2025","unstructured":"Lee JW, Jang JH, Chiba S, Yoon SS, Oshikawa G, Usuki K. Romiplostim with ciclosporin A in patients with aplastic anaemia na\u00efve to immunosuppressive therapy: a phase 2\/3 study. Br J Haematol. 2025;207:582\u201390.","journal-title":"Br J Haematol"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00152-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00152-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00152-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:56:41Z","timestamp":1785491801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00152-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["152"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00152-3","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"39"}}